Elevance Health said fourth-quarter operating revenue was $45.0 billion and full-year operating revenue was $175.2 billion. Full-year diluted EPS was $25.68, and adjusted diluted EPS was $33.04. For Q4, diluted EPS was $1.81 and adjusted diluted EPS was $3.84.

1. 01

   Elevance Health said fourth-quarter operating revenue was $45.0 billion and full-year operating revenue was $175.2 billion. Full-year diluted EPS was $25.68, and adjusted diluted EPS was $33.04. For Q4, diluted EPS was $1.81 and adjusted diluted EPS was $3.84.

2. 02

   The company said its benefit expense ratio was 92.4% in Q4, up 320 basis points from the prior-year period, and 88.5% for the full year, up 150 basis points year over year. The company cited higher Medicaid medical cost trends as the main driver of the increases.

3. 03

   The company said operating cash flow was $5.8 billion in 2024. In Q4, it repurchased 4.5 million shares for $1.8 billion and paid a dividend of $1.63 per share. As of December 31, 2024, about $9.3 billion remained under its Board-approved share repurchase authorization.

4. 04

   The company said it expects full-year 2025 GAAP diluted EPS in the range of $30.40 to $31.10 and adjusted diluted EPS in the range of $34.15 to $34.85. It also announced a quarterly dividend increase of 5% to $1.71 per share.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.